ASTRANA HEALTH INCASTH
ASignal's systematic analysis rates ASTH as Neutral.
Reflects the latest available analysis · analyzed Sep 12, 2026
The case on ASTH
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong year-over-year revenue growth (48.5%)
- Exceptional earnings growth (110.5% YoY)
- Free cash flow significantly exceeds net income
- Forward P/E of 10.73x suggests valuation improvement
- EV/Revenue of 0.60x indicates undervaluation relative to sales
- High debt-to-equity ratio (1.64x)
- Low net and operating margins (1.05% and 3.53%)
- Current price below 20-day EMA (38.33)
- MACD still negative despite bullish crossover signal
- Financial health score in bottom tier (0.35)
See the full verdict on ASTH
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes ASTH
Most investors never get a second opinion, let alone several. ASignal runs ASTH past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.